期刊文献+

肺吸入用微粒的粉体工程学技术研究进展 被引量:1

Advances in particle engineering techniques for pulmonary drug delivery
下载PDF
导出
摘要 近年来,药物的肺部递送作为一种非侵入性的给药途径引起了广泛关注,肺部给药的市场需求也不断增加。各种粉体工程学技术被用于开发具有合适物理性质的用于肺部递送的药物颗粒,这些经过设计的药物颗粒为高效的肺部递送和最优的治疗效果提供了可能。本文重点阐释了肺部颗粒的沉积机制以及各种粉体工程技术在肺部给药领域中的应用,其中Pulmo Sphere^(TM)和Techno Sphere^(TM)两种新技术已用于上市产品的生产。 In recent years,pulmonary drug delivery as an attractive non-invasive administration way has been gaining intensive attention. The market for inhalable therapy has constantly grown over past years. Various particle engineering techniques have been employed to exploit the drug particles or drug-loaded particles used for pulmonary delivery with suitable physical properties.Those tailor-made inhalable particles offer the possibility of efficient delivering to lungs and the most optimal therapeutic outcomes.This review highlights the deposition mechanism of particles in lungs and several particle engineering techniques for pulmonary drug delivery,in particular two novel techniques Pulmo Sphere^(TM) and Techno Sphere^(TM),which have been used in the marketed products。
作者 谌茜
出处 《国际药学研究杂志》 CAS CSCD 北大核心 2016年第3期455-460,共6页 Journal of International Pharmaceutical Research
关键词 粉体工程技术 肺部给药 微粉化 结晶控制 喷雾干燥 冷冻干燥 超临界流体 particle engineering techniques pulmonary drug delivery micronization controlled crystallization spray drying freeze drying supercritical fluid
  • 相关文献

参考文献42

  • 1Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery [J]. Med Res Rev, 2009, 29(1): 196-212.
  • 2Rogueda PG, Traini D. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects [J]. Expert Opin Drug Deliv, 2007, 4(6): 595-606.
  • 3Shekunov BY, Chattopadhyay P, Tong HH, et al. Particle size analysis in pharmaceutics: principles, methods and applications [J]. Pharm Res, 2007, 24(2): 203-227.
  • 4Hickey AJ, Martonen TB, Yang Y. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols [J]. Pharm Acta Helv, 1996, 71(3): 185-190.
  • 5Mackin L, Zanon R, Park JM, et al. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry [J]. Int J Pharm, 2002, 231(2): 227-236.
  • 6Young PM, Chiou H, Tee T, et al. The use of organic vapor sorption to determine low levels of amorphous content in processed pharmaceutical powders [J]. Drug Dev Ind Pharm, 2007, 33(1): 91-97.
  • 7Brodka-Pfeiffer K, H?usler H, Grass P, et al. Conditioning following powder micronization: influence on particle growth of salbutamol sulfate [J]. Drug Dev Ind Pharm, 2003, 29(10): 1077-1084. approach on the aerosol performance of micronized drug powders from dry powder inhalers [J]. AAPS PharmSciTech, 2013, 14(1): 38-44.
  • 8Hüttenrauch R, Fricke S, Zielke P. Mechanical activation of pharmaceutical systems [J]. Pharm Res, 1985, 2(6): 302-306.
  • 9Shur J, Pitchayajittipong C, Rogueda P, et al. Effect of processing history on the surface interfacial properties of budesonide in carrier-based dry-powder inhalers [J]. Ther Deliv, 2013, 4(8): 925-937.
  • 10Zhou QT, Qu L, Larson I, et al. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach [J]. Int J Pharm, 2010, 394(1/2): 50-59.

同被引文献21

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部